Valeant Pharmaceuticals is to acquire OraPharma, an oral health company from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. Total deal value is around $312 million.
PRESS RELEASE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry.
